Effect of hemodialysis on platelet function in end-stage renal disease Egyptian patients using <i>in vitro</i> closure time test (PFA-100 analyzer)

Mekawy, Mohamed; Habashy, Deena Mohamed; El-Mohsen, Waleed A M Abd

doi:10.3109/09537104.2014.931569

Cited by 13 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…37,38 In this present study platelet count and other platelet indices were improved, similar findings seen in other studies. 11,28,29 In our study, there was decrease in haemoglobin and haematocrit values in patients before haemodialysis session compared to controls. These values were increased in patients after haemodialysis.…”

Section: Discussionsupporting

confidence: 44%

Coagulation Profile and Platelet Indices in Diabetes with Chronic Kidney Disease on Haemodialysis

Mittra¹,

Pandey²

2019

IJCMR

View full text Add to dashboard Cite

Introduction: Bleeding and thrombotic complications are high possibility in CKD. The present study was conducted to evaluate the platelets indices in patients on haemodialysis having Type 2 diabetes with CKD as compared to diabetic patients without CKD. Material and methods: 100 patients of ckd with diabetes and 100 patients of diabetes without ckd were studied over a period of seven months. The coagulation profile and platelet indices were compared. The coagulation profile and platelet indices were also compared in ckd patients before and after dialysis. Results: Increase in platelet indices mainly MPV and Platelet Distribution Width (PDW) with significant p-value 0.003 and 0.005 respectively in study group. PT and APTT both were increased in study group with significant p-value of 0.003. Platelet count improved but MPV and PDW values were slightly decreased with p-value < 0.005. PT showed not much difference whereas APTT values were higher compare to post dialysis with p-value<0.007. Conclusion: Basic coagulation profile like PT and APTT and MPV can predict long term complications of diabetic platelets on haemodialysis and these should be monitored in CKD patients.

show abstract

Section: Discussionsupporting

confidence: 44%

Coagulation Profile and Platelet Indices in Diabetes with Chronic Kidney Disease on Haemodialysis

Mittra¹,

Pandey²

2019

IJCMR

View full text Add to dashboard Cite

show abstract

“…10 The presence of uremic substances like urea, guanidine succinate, phenol, parathyroid hormone, and tryptophan products inhibits platelet function. 11 Parathyroid hormone was not significantly different between the two RRT groups (p ¼ 0.88). However, urea significantly differed between the two groups (p ¼ 0.003) and was therefore added into the hierarchical multiple linear regression model.…”

Section: Discussionmentioning

confidence: 85%

“…90% of the patients had a predialysis CT prolongation that returned to normal ranges in 22% of those patients after the HD session. 11 Besides that, Knehtl et al 20 compared PFA-100 of chronic HD patients before and after HD sessions with five different anticoagulation methods (full-dose unfractionated heparin, low-molecular-weight heparin, low-dose heparin, regional citrate, and heparin-free) and did not observe any improvements between pre-and postdialysis values and any differences between different types of anticoagulation methods. 18 Concerning our HD patients, all received full-dose heparin (5,000 I.U./session) during the HD session but it is known that heparin does not affect CT. 19 PD may be more effective in normalizing primary hemostasis caused by uremia than HD due to relatively higher hematocrit levels, an absence of platelet activation by artifi-cial surfaces, and improved clearance of middle molecules.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Closure Times (PFA-100) Are Different Between Peritoneal Dialysis and Hemodialysis

et al. 2020

View full text Add to dashboard Cite

Introduction Platelet dysfunction is not uncommon in patients with end-stage renal disease (ESRD). Type of renal replacement therapy may have an effect on platelet functions, which has not been well investigated. We evaluated in vitro closure time (CT) differences between peritoneal dialysis (PD) and hemodialysis (HD) patients using platelet function analyzer (PFA-100)and observed a significant difference between these renal replacement therapies. Methods Patients with ESRD undergoing PD (n = 24) or HD (n = 23) for more than 6 months were included. Blood samples for collagen/epinephrine (Col/EPI) and collagen/adenosine diphosphate (Col/ADP) measurements were obtained before HD at a mid-week session for HD patients and at an outpatient control time for PD patients. Results Three of 24 (12.5%) PD patients and 16 of 23 (69.5%) HD patients had prolonged PFA-100 Col/EPI, p< 0.001. Likewise, 4.2% of PD patients and 87.0% of HD patients had prolonged PFA-100 Col/ADP, p< 0.001. Moreover, the median times of PFA-Col/EPI and PFA-100 Col/ADP were significantly lower in PD patients compared with those of HD patients (p< 0.001). Multivariate analysis showed that the type of renal replacement was a risk factor for both elevated PFA-100 Col/ADP and PFA-100 Col/EPI after adjusted for platelets, hematocrit, and urea (p< 0.001). Conclusions The type of renal replacement therapy may have an effect on in vitro CTs; therefore, studies including more patients with long-term follow-up are needed to investigate if the difference has any impact on clinical outcomes.

show abstract

“…Both mean PLT volume and PLT distribution width were reported to be decreased in patients with mild cognitive impairment and Alzheimer’s disease 39 . In addition, PLTs were previously shown to be exhausted after hemodialysis because of repeated hemodialysis stimulation and recurrent release of PLT degranulation products 40 . The results of the current study showed that blood PLT counts were significantly decreased in hemodialysis patients with MCD than that of healthy control individuals and hemodialysis patients with NCF.…”

Section: Discussionmentioning

confidence: 99%

Differential expression of serum biomarkers in hemodialysis patients with mild cognitive decline: A prospective single-center cohort study

Zhu

Jin

Shen

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Studies suggest that hemodialysis patients are at a higher risk for cognitive decline than healthy individuals; however, underlying mechanisms have not been fully elucidated. We aimed to investigate the roles of serum biomarkers, such as brain-derived neurotrophic factor (BDNF), inflammatory cytokines, fibroblast growth factor (FGF)-23 and its co-receptor α-klotho and platelet (PLT) count in mild cognitive decline (MCD) of patients undergoing hemodialysis in this prospective cohort study. Serum levels of BDNF, tumour necrosis factor (TNF)-α, interleukin (IL)-6 and the number of PLT were significantly altered in the MCD group compared with those in healthy controls (HCs) or those with normal cognitive function (NCF). Although serum α-klotho and FGF-23 levels were significantly altered in the MCD group, there were no statistical differences between the MCD and NCF groups. Serum BDNF levels and PLT counts were significantly correlated with cognitive test scores. Receiver operating characteristic (ROC) curves demonstrated that BDNF and PLT were potential biomarkers for improved MCD diagnosis in patients with hemodialysis. These findings suggest that hemodialysis-related MCD is associated with altered BDNF, TNF-α and IL-6 levels as well as PLT counts and that serum BDNF levels and PLT counts are potential biomarkers for hemodialysis-related MCD diagnosis.

show abstract

Effect of hemodialysis on platelet function in end-stage renal disease Egyptian patients using in vitro closure time test (PFA-100 analyzer)

Cited by 13 publications

References 18 publications

Coagulation Profile and Platelet Indices in Diabetes with Chronic Kidney Disease on Haemodialysis

Coagulation Profile and Platelet Indices in Diabetes with Chronic Kidney Disease on Haemodialysis

In Vitro Closure Times (PFA-100) Are Different Between Peritoneal Dialysis and Hemodialysis

Differential expression of serum biomarkers in hemodialysis patients with mild cognitive decline: A prospective single-center cohort study

Contact Info

Product

Resources

About